RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 158 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,530,000 | -43.9% | 200,000 | -45.2% | 0.01% | -57.9% |
| Q2 2023 | $2,726,550 | -2.7% | 365,000 | -13.1% | 0.02% | -29.6% |
| Q1 2023 | $2,801,400 | -9.2% | 420,000 | +5.0% | 0.03% | -50.0% |
| Q4 2022 | $3,084,000 | -3.4% | 400,000 | +33.3% | 0.05% | +50.0% |
| Q3 2022 | $3,192,000 | +30.7% | 300,000 | 0.0% | 0.04% | +24.1% |
| Q2 2022 | $2,442,000 | +13.7% | 300,000 | 0.0% | 0.03% | +11.5% |
| Q1 2022 | $2,148,000 | -55.2% | 300,000 | +7.1% | 0.03% | -50.0% |
| Q4 2021 | $4,796,000 | -21.4% | 280,000 | +5.7% | 0.05% | -16.1% |
| Q3 2021 | $6,098,000 | -33.8% | 265,000 | +5.0% | 0.06% | -18.4% |
| Q2 2021 | $9,216,000 | – | 252,500 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 10,405,668 | $79,603,360 | 100.00% |
| Data Collective IV GP, LLC | 5,941,120 | $45,449,568 | 43.00% |
| MIC Capital Management UK LLP | 8,451,758 | $64,655,952 | 14.74% |
| MV Management XI, L.L.C. | 788,762 | $6,034,029 | 10.04% |
| ArchPoint Investors | 1,047,386 | $8,012,503 | 3.06% |
| Connective Portfolio Management, LLC | 33,000 | $252,000 | 0.77% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,335,132 | $17,863,760 | 0.70% |
| Diametric Capital, LP | 136,331 | $1,042,932 | 0.44% |
| ARK Investment Management | 6,876,598 | $52,605,973 | 0.40% |
| ALLEN OPERATIONS LLC | 217,657 | $1,665,076 | 0.37% |